SecurityBSE:532978 / BAJAJ FINSERV LTD.
Institutional Owners0

Institutional Stock Ownership and Shareholders()

BAJAJ FINSERV LTD. (BSE:532978) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include .
BAJAJ FINSERV LTD. (BSE:532978) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Important Note!
Note: We do not currently have a CUSIP on file for this security. That means we are unable to search institutional fund filings (13F's) for this company, which means there may be institutional holders that we are unaware of. If you know the CUSIP or would like us to research and update this security, please let us know by leaving a message in the Welcome Group.
File DateFormInvestor Opt Prev
Prev Value
Current Value

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

4h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

6h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

D-Street Buzz: Nifty midcap, pharma shed 2-3% dragged by Dr Reddy#39;s Labs, JP Associates; PC Jeweller plummets 25%

23h moneycontrol
The Indian benchmark indices this Monday afternoon with the Nifty trading lower by 57 points at 10,961 while the Sensex is down 118 points at 36,423. (4-0)

D-Street Buzz: Nifty Pharma underperforms as Dr Reddy#39;s plunges 9%; HUL hits record high, Infosys up 3%

2018-07-16 moneycontrol
The Indian benchmark indices including the Nifty is trading lower by 36 points at 10,981 while the Sensex is down 67 points at 36,474. (4-0)

D-Street Buzz: Over 131 stocks hit new 52-week low on NSE with PC Jeweller down 20%, RIL slips 2%

2018-07-16 moneycontrol
After hitting record high last week, the Indian benchmark indices including the Sensex has turned weak and is trading lower by 16 points at 36,569 while the Nifty is trading lower by 5 points at 11,017. (4-0)

D-Street Buzz: Nifty PSU bank underperforms with IDBI Bank down 6%; RIL hits new record high, Wipro gains 2%

2018-07-13 moneycontrol
After hitting record high yesterday, the Indian benchmark indices including the Sensex has turned weak and is trading higher by 16 points at 36,569 while the Nifty is trading lower by 5 points at 11,017. (1-0)

Closing Bell: Banks, RIL lift Sensex 267 pts; Nifty ends above 10,750 despite weak Asia

2018-07-04 moneycontrol
Global Update: Asian markets ended in the red with China's Shanghai Composite losing a percent after recording gains in the previous session. Trade tensions remained in the spotlight ahead of a looming tariff deadline, reports CNBC. (1-0)